Teplizumab

Unassigned

New Medicines

Type 1 diabetes mellitus - prevention in very high-risk pts

Information

New molecular entity
MacroGenics
MacroGenics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

CD3 antagonist. Proposed to inhibit autoimmune destruction of insulin-producing pancreatic beta cells in patients with type 1 diabetes
Currently, 3.8 million people in the UK are diagnosed with diabetes. Up to 1 million people have type 2 diabetes that is yet to be diagnosed, so the total is estimated to be 4.7 million people at present. This represents 7% of the UK population (1 in every 15 people) having diabetes (diagnosed and undiagnosed). 10% have type 1 diabetes [21]. Incidence is increasing by about 4% each year, particularly in children under five, with a 5% increase each year in this age group [22].
Type 1 diabetes mellitus - prevention in very high-risk pts
Intravenous